Bibliographie : Interactions et antagonisme THC - CBD Docteur Christian SUEUR, GRECC, mars 2020. Les interactions entre le THC et le CBD sur le système endocannabinoide, quant aux effets psychotomimetic (production de "symptomes psychotiques") sont opposés : là où le THC produit préférentiellement de l'anxiété, et des effets "psychotisants", le CBD est plutôt anxiolytique et "antipsychotique". Ces deux phytocannabinoïdes sont "antagonistes", et contribuent, parmi d'autres inter-relations entre les phytocannabinoïdes, les terpènes et les flavonoïdes composant le cannabis, aux "effets d'entourage" fondamentaux, tout autant quant à la production "d'effets indésirables" et de risques pour la santé mentale du consommateur, que dans le cadre de [...]
Lire la suiteCannabis for pediatric epilepsy : protocol for a living systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Bláthnaid McCoy and George A. Wells Systematic Reviews, 2018, 7, 95 doi : 10.1186/s13643-018-0761-2 Abstract Background : Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life, morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of cannabis use in this population. In this systematic review, we will [...]
Lire la suiteCannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats Karina Genaro, Débora Fabris, Ana L. F. Arantes, Antônio W. Zuardi, José A. S. Crippa and Wiliam A. Prado Frontiers in Pharmacology, June 2017 | Volume 8 | Article 391 doi : 10.3389/fphar.2017.00391 Background : Pain involves different brain regions and is critically determined by emotional processing. Among other areas, the rostral anterior cingulate cortex (rACC) is implicated in the processing of affective pain. Drugs that interfere with the endocannabinoid system are alternatives for the management of clinical pain. Cannabidiol (CBD), a phytocannabinoid found in Cannabis sativa, has been utilized [...]
Lire la suiteCannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs Hector LAFUENTE, Francisco J. ALVAREZ, M. Ruth PAZOS, Antonia ALVAREZ, M. Carmen REY-SANTANO, Victoria MIELGO, Xabier MURGIA-ESTEVE, Enrique HILARIO, and Jose MARTINEZ-ORGADO Pediatric Research, 2011, 70, 272–277. ABSTRACT : Newborn piglets exposed to acute hypoxia-ischemia (HI) received i.v. cannabidiol (HI CBD) or vehicle (HI VEH). In HI VEH, 72 h post-HI brain activity as assessed by amplitudeintegrated EEG (aEEG) had only recovered to 42 9% of baseline, near-infrared spectroscopy (NIRS) parameters remained lower than normal, and neurobehavioral performance was abnormal (27.8 2.3 points, normal 36). [...]
Lire la suiteA single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study Khalid A. Jadoon, Garry D. Tan, and Saoirse E. O’Sullivan JCI Insight, 2017, 2, (11), e93760 Doi : 10.1172/jci.insight.93760 BACKGROUND. Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid used in multiple sclerosis and intractable epilepsies. Preclinical studies show CBD has numerous cardiovascular benefits, including a reduced blood pressure (BP) response to stress. The aim of this study was to investigate if CBD reduces BP in humans. METHODS. Nine healthy male volunteers were given 600 mg of CBD or placebo in a randomized, placebo-controlled, double-blind, crossover study. Cardiovascular parameters were monitored using [...]
Lire la suiteCannabidiol protects an in vitro model of the blood–brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors William H Hind, Timothy J England and Saoirse E O’Sullivan British Journal of Pharmacology, 2016, 173, 815–825. Doi : 10.1111/bph.13368 BACKGROUND AND PURPOSE In vivo and in vitro studies have demonstrated a protective effect of cannabidiol (CBD) in reducing infarct size in stroke models and against epithelial barrier damage in numerous disease models. We aimed to investigate whether CBD also affects blood–brain barrier (BBB) permeability following ischaemia. EXPERIMENTAL APPROACH Human brain microvascular endothelial cell (HBMEC) and human astrocyte co-cultures modelled the BBB. Ischaemia was modelled by oxygen–glucose deprivation (OGD) [...]
Lire la suiteCannabis as Medicine: How CBD (Cannabidiol) Benefits the Brain and Nervous System Audrey Lefebvre wakeup-world.com/2016/03/20/cannabis-as-medicine-how-cbd-cannabidiol-benefits-the-human-brainand-nervous-system/ Cannabidiol (CBD) is an active cannabinoid found in cannabis which, unlike THC (tetrahydro-cannabinol), does not produce a psychoactive effect in the brain. For this reason, CBD has become a primary focus of medicinal cannabis studies. CBD has been found to have a wide range of benefits, including lowering blood sugar levels, promoting bone growth, and importantly, protecting the human brain and nervous system from degeneration. How CBD Protects the Nervous System The nervous system is comprised of two main parts: the peripheral nervous system, which includes the nerves and ganglia on [...]
Lire la suiteIs there a role for cannabidiol in psychiatry ? Julia Machado Khoury , Maila de Castro Lourenço das Neves, Marco Antônio Valente Roque, Daniela Alves de Brito Queiroz , Andre Augusto Corrêa de Freitas, Angelo de Fatima, Fabrıcio Moreira and Frederico Duarte Garcia The World Journal of Biological Psychiatry, 2017, 16 p. Doi : 10.1080/15622975.2017.1285049 ABSTRACT Objectives : Understanding whether cannabidiol (CBD) is useful and safe for the treatment of psychiatric disorders is essential to empower psychiatrists and patients to take good clinical decisions. Our aim was to conduct a systematic review regarding the benefits and adverse events (AEs) of CBD in the treatment of schizophrenia, psychotic [...]
Lire la suiteComprehensive classification of USA cannabis samples based on chemical profiles of major cannabinoids and terpenoids Ramia Z. Al Bakain, Yahya S. Al-Degs, James V. Cizdziel and Mahmoud A. Elsohly Journal of Liquid Chromatography & Related Technologies, 2019 Doi : 10.1080/10826076.2019.1701015 ABSTRACT Different USA-origin cannabis samples were analyzed by GC-FID to quantify all possible cannabinoids and terpenoids prior to their clustering. Chromatographic analysis confirmed the presence of seven cannabinoids and sixteen terpenoids with variable levels. Among tested cannabinoids, D9-Tetrahydro-cannabinol D9-THC and cannabinol CBN were available in excess amounts (1.2–8.0 wt%) and (0.22–1.1 wt%), respectively. Fenchol was the most abundant terpenoid with a range of (0.03–1.0 wt%). [...]
Lire la suiteCannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial mesenchymal transition in vitro Lara Milian, Manuel Mata, Javier Alcacer, Marıa Oliver, Marıa Sancho-Tello, Jose Javier Martın de Llano, Carlos Camps, Jose Galbis, Julian Carretero, Carmen Carda PLoS ONE, 2020, 15, (2): e0228909. Doi : 10.1371/journal.pone.0228909 Abstract Background/Objective : Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT). This necessitates the development of new complementary drugs, e.g., cannabinoid receptors (CB1 and CB2) agonists including tetrahydro-cannabinol (THC) and cannabidiol (CBD). The combined use of THC and CBD [...]
Lire la suite